ライフサイエンスコーパス: procoagulant

1 r proteins found in blood (eg, tissue factor procoagulant).

2 are small membrane vesicles that are highly procoagulant.

3 ured endothelial cells rendering them highly procoagulant.

4 ansformation platelets undergo when becoming procoagulant.

5 se VTE risk through elevated levels of these procoagulants.

6 clotting times, it appeared to exert all its procoagulant actions upstream of thrombin.

7 factors to phosphatidylserine (PS)-exposing procoagulant-activated platelets followed by formation o

8 in both TUNEL(+) endothelial cell death and procoagulant activation (increased expression of both ti

9 endothelial cell death, diffuse endothelial procoagulant activation with high expression of tissue f

10 nflammatory signaling and tissue factor (TF) procoagulant activation.

11 tion of anticoagulant and down-regulation of procoagulant activities in response to the local environ

12 s some existing knowledge gaps regarding the procoagulant activities of neutrophil-derived extracellu

13 MP-TF assays revealed high procoagulant activity (9.05 +/- 8.82 versus 0.24 +/- 0.1

14 on endothelial and blood cells and to assess procoagulant activity (PCA) as a function of the stage o

15 examined the effect of platelet clearance on procoagulant activity (PCA) in sepsis.

16 We found that ATG activated tissue factor procoagulant activity (TF PCA) on monocytic cells more p

17 s) to determine their ability to block polyP procoagulant activity and also to determine their utilit

18 ontribute to disease progression through its procoagulant activity and its capacity to induce intrace

19 ne 209 (Cys186-Cys209) bond formation for TF procoagulant activity and its de-encryption.

20 +)-dependent phosphatidylserine exposure and procoagulant activity and lack a Ca(2+)-activated cation

21 edback loop, mediating a subsequent surge in procoagulant activity and microvesicle release.

22 P2rx7) induced activation (decryption) of TF procoagulant activity and promoted release of TF+ MPs fr

23 generates new evidence implicating increased procoagulant activity and thrombin generation in the dem

24 An enhancement of platelet procoagulant activity appears to be an additional and (a

25 e-linked immunosorbent assay, and heparanase procoagulant activity assay.

26 e-linked immunosorbent assay, and heparanase procoagulant activity assay.

27 (C209S), or TF(C186S/C209S) expressed little procoagulant activity at the cell surface.

28 Factor Xa has procoagulant activity by conversion of prothrombin to th

29 sP-selectin enhances procoagulant activity by inducing leukocyte-derived micr

30 n in PDEVs, which was reflected in the lower procoagulant activity compared to those generated withou

31 lation by inhibiting FXI activation or FXIIa procoagulant activity during sepsis may therefore limit

32 prethrombin-2 pathway serves to optimize the procoagulant activity expressed by activated platelets,

33 enhanced lipopolysaccharide (LPS)-induced TF procoagulant activity in monocytes.

34 this novel mechanism in the regulation of TF procoagulant activity in pathophysiology.

35 dy reduced the increased prostasome-mediated procoagulant activity in patient plasma.

36 eral UHRA compounds strongly inhibited polyP procoagulant activity in vitro, and 4 were selected for

37 ion, but had minimal impact on tissue factor procoagulant activity in vitro, were conjugated with the

38 pJ mice bind to various antigens and exhibit procoagulant activity in vitro.

39 Procoagulant activity is destroyed by phospholipase C tr

40 The enhanced procoagulant activity is fully retained in plasma unless

41 Importantly, procoagulant activity is increased by the presence of an

42 Excess procoagulant activity is linked with pathological thromb

43 blockade by antibody or shRNA diminished the procoagulant activity of EMT-positive cells, confirming

44 hesis that formation of thrombin through the procoagulant activity of FVIII is necessary to induce co

45 t activation and is responsible for the full procoagulant activity of FXII.

46 phate nanoparticles mechanistically link the procoagulant activity of platelets with the activation o

47 Polyphosphate content correlated with the procoagulant activity of prostasomes.

48 also compare their effectiveness against the procoagulant activity of RNA.

49 king increases availability of TF-FVIIa with procoagulant activity on the cell surface, while inhibit

50 ti-GRP78 AutoAbs increase tissue factor (TF) procoagulant activity on the surface of tumor cells, the

51 ta indicate that LPS- or cytokine-induced TF procoagulant activity requires the decryption of newly s

52 ion assay, they displayed significantly more procoagulant activity than particles derived from cells

53 Skeletal muscle myosin has potent procoagulant activity that is based on its ability to en

54 Procoagulant activity was assessed by a functional MP-ti

55 Prostate cancer-mediated procoagulant activity was reduced in plasma in the absen

56 SMase inhibitors also blocked LPS-induced TF procoagulant activity without affecting the LPS-induced

57 associated with phosphatidylserine exposure (procoagulant activity), and this too was blocked in GPVI

58 Higher heparanase levels, heparanase and TF procoagulant activity, and erythropoietin levels were fo

59 secondary structure may be important to its procoagulant activity, and that nucleic acids versus pol

60 in activation, granule release, aggregation, procoagulant activity, and thrombin generation in respon

61 accelerated thrombus formation and enhanced procoagulant activity, assembling a prothrombotic phenot

62 ther mAb, designated group B, inhibits fVIII procoagulant activity, fVIII binding to VWF and phosphol

63 though fibrin structure depended on cellular procoagulant activity, it did not reflect interactions b

64 g affinities for fVIII, weakly inhibit fVIII procoagulant activity, poorly inhibit fVIII binding to p

65 ty of fVIII potentially is a function of its procoagulant activity, which may result in danger signal

66 ion, implicating TFPI in modulating platelet procoagulant activity.

67 HIT antibodies, with increased phospholipid procoagulant activity.

68 ng von Willebrand factor (VWF), reducing its procoagulant activity.

69 ta3 activation, alpha-granule secretion, and procoagulant activity.

70 ncluding platelet adhesion, aggregation, and procoagulant activity.

71 generation of factor Va (fVa) are vital for procoagulant activity.

72 the transcription of TF and consequently its procoagulant activity.

73 s, and on microparticles (MPs) with variable procoagulant activity.

74 ies have shown that polyphosphate has potent procoagulant activity.

75 le of ASMase in LPS- and cytokine-induced TF procoagulant activity.

76 ent and TF expression, indicative of reduced procoagulant activity.

77 oncentration, protein concentration, and BAL procoagulant activity.

78 dense granules of activated platelets, is a procoagulant agent.

79 others have previously shown that thrombin's procoagulant and anticoagulant activities can be effecti

80 The balance between actions of procoagulant and anticoagulant factors protects organism

81 sfunction and affect the equilibrium between procoagulant and anticoagulant systems, contributing to

82 portant in determining their ability to bind procoagulant and anticoagulant/fibrinolytic serine prote

83 Because factor XI displays both procoagulant and antifibrinolytic activities, it has bee

84 xpression led to a significant inhibition of procoagulant and antifibrinolytic pathways.

85 e bacterial sepsis often leads to a systemic procoagulant and proinflammatory condition that can mani

86 R/PC-binding interactions not only result in procoagulant and proinflammatory effects, but also impac

87 is the protein substrate of the multifaceted procoagulant and proinflammatory enzyme, thrombin.

88 In addition to its procoagulant and proinflammatory functions mediated by c

89 namic process that leads to the formation of procoagulant and proinflammatory platelets under physiol

90 ctions between GGS and the contact system, a procoagulant and proinflammatory proteolytic cascade tha

91 Procoagulant and proinflammatory responses were assessed

92 ens can activate the endothelial cell into a procoagulant and proinflammatory surface, the two pathwa

93 of neutrophil extracellular traps (NETs), is procoagulant and prothrombotic.

94 cluster, we observed reduced TF expression, procoagulant and TF signaling activities (responses to f

95 Treatments with procoagulants and platelet antagonists and studies with

96 gulation of pro-inflammatory, proliferative, procoagulant, and profibrotic genes; and at 4 weeks, the

97 ping novel antithrombotic agents that target procoagulant anionic polymers such as polyP with reduced

98 some cancer patients by profoundly disturbed procoagulant-anticoagulant balance, whereby warfarin fai

99 such as B. subtilis, can shift the delicate procoagulant-anticoagulant equilibrium toward thrombosis

100 Unlike blebbing, procoagulant ballooning is irreversible and a consequenc

101 t circulating platelets are transformed into procoagulant balloons within minutes of injury, accompan

102 All MPs are procoagulant because they provide a membrane surface for

103 PG showed that FOG and PG both activate the procoagulant branch of the contact system.

104 might be released during injury, can act as procoagulants by providing membrane-like support for fac

105 The MV procoagulant capacity was also significantly greater.

106 t glomerulopathy and capillaropathy); (b) EC procoagulant changes: EC activation and disruption of th

107 cular coagulation, by reducing the number of procoagulant circulating microparticles and therefore de

108 Thrombin alone is a procoagulant, cleaving fibrinogen to make the fibrin clo

109 g with the 4-carboxyglutamic acid domains of procoagulant coagulation factors VII (FVII) and X (FX).

110 platelets, consistent with the formation of procoagulant coated platelets.

111 Generation of active procoagulant cofactor factor Va (FVa) and its subsequent

112 reby creating a potent constitutively active procoagulant cofactor.

113 PAR-1, but not for its interaction with the procoagulant cofactors.

114 itiated reactions with fresh reactants, that procoagulant complexes are produced during Tf-initiated

115 Prothrombin is the dominant procoagulant component of PCC and could limit bleeding i

116 rdiopulmonary bypass (CPB), induces a highly procoagulant condition requiring strong anticoagulation.

117 Moreover, FVIII-RH exhibits superior procoagulant effects compared with FVIII-BDD following a

118 Moreover, the complement activation and the procoagulant effects of the beta2-GPI/MBL complex may co

119 up box 1 exerts powerful proinflammatory and procoagulant effects on WT PAEC, and appears to be an im

120 americ core histones reproduced any of these procoagulant effects.

121 orresponding proteome mixtures as sources of procoagulant end products and then varied the resupplyin

122 ave an elevated circulating concentration of procoagulant endothelial microparticles (MPs), leading t

123 enetic models demonstrate a central role for procoagulant enzymatically oxidized phospholipids (eoxPL

124 We postulate that procoagulant events in the tissue microenvironment (nich

125 down-regulates LPS-mediated inflammatory and procoagulant expression by modulating actin organization

126 ch was related to poor outcome while hepatic procoagulant factor II remained unaffected.

127 We sought to identify the dominant procoagulant factor in PCC in vivo.

128 g disorders characterized by deficiencies in procoagulant factor VIII (FVIII) or factor IX (FIX), res

129 ted hydrolysis of a model protein substrate, procoagulant factor VIII, did not correlate with that of

130 Because FIXa is an upstream procoagulant factor, impaired AT regulation of FIXa migh

131 Higher levels of procoagulant factors and factor XII deficiency may be ri

132 hysiologic consequences, explaining why many procoagulant factors are delivered both in the plasma an

133 In times of vitamin K insufficiency, hepatic procoagulant factors are preferentially activated over e

134 vesicles, called microparticles, disseminate procoagulant factors from the brain into the systemic ci

135 ned whether activated platelets and systemic procoagulant factors were associated with VTE in 32 olde

136 a modest increase in the activity of several procoagulant factors, but there was no difference in the

137 Among these procoagulant factors, only elevated factor XI was a risk

138 m integrity is associated with production of procoagulant factors, platelet aggregation, and facilita

139 and prolonged repletion of some but not all procoagulant factors.

140 lant-inactive state but are transformed to a procoagulant form (decryption) following cell activation

141 B domain deleted (BDD) FVIII retains full procoagulant function and is expressed at higher levels

142 These antibodies block (inhibit) the procoagulant function of FVIII and thus are termed "inhi

143 Va is partially responsible for the enhanced procoagulant function of prothrombinase.

144 Furthermore, the BR inhibits procoagulant function of the variants, thereby restoring

145 TM-mediated regulation of tumor cell-driven procoagulant function strongly influences metastatic pot

146 ants require factor Va generated in situ for procoagulant function, and cofactor inactivation by the

147 t ThbdPro mice, which have elevated thrombin procoagulant function, gained more weight and developed

148 mune response to fVIII is independent of its procoagulant function, is both positively and negatively

149 ial clearance was dependent on (pro)thrombin procoagulant function, supporting a suspected role for f

150 surface PDI induces a marked increase in TF procoagulant function, whereas exogenous addition of PDI

151 latelet activation, aggregation, or platelet procoagulant function.

152 r cell-associated tissue factor and thrombin procoagulant function.

153 latelet phosphatidylserine (PS) exposure and procoagulant function.

154 eading to decreased platelet PS exposure and procoagulant function.

155 al to mFVIIa with respect to TF affinity and procoagulant functions.

156 r site for expression of proinflammatory and procoagulant genes during acute systemic inflammation.

157 may contribute to the toxic inflammatory and procoagulant host response to endotoxin.

158 bin complexes, and D-dimers were measured as procoagulant markers and markers of activation of coagul

159 ease, malignancy, genetic thrombophilia, and procoagulant markers) were adjusted for when comparing p

160 ions between leukocytes or leukocyte-derived procoagulant materials and the traditional hemostatic sy

161 Microbial polyphosphate, which is highly procoagulant, may function in host responses to pathogen

162 We identify a new procoagulant mechanism that contributes to thromboemboli

163 Despite a profound upregulation in procoagulant mechanisms, one-quarter of trauma patients

164 ecificity for inhibition of myosin-dependent procoagulant mechanisms.

165 Leukocyte-released procoagulant mediators increase systemic thrombogenicity

166 ous studies showed that cultured ECs release procoagulant mediators into cell culture supernatants as

167 tin expression, microparticle formation, and procoagulant membrane changes, regardless of the activat

168 n unexpectedly important role in providing a procoagulant membrane surface in vivo.

169 f inhibition of FXa by the ZPI-PZ complex on procoagulant membrane vesicles (k(a) ((app)) ~10(7) m(-1

170 PI and its cofactor, protein Z (PZ), inhibit procoagulant membrane-bound factor Xa by the branched pa

171 ctivity relative to FVIIa upon exposure to a procoagulant membrane.

172 in a manner uniquely dependent on protein Z, procoagulant membranes, and pH.

173 on of extracellular thiol pathway-dependent, procoagulant microparticles (MPs).

174 Procoagulant microparticles from endothelial cells and l

175 ote thrombosis is by inducing the release of procoagulant microparticles from endothelial cells.

176 or instance, tumor cells release TF-positive procoagulant microparticles into the circulation and the

177 itization of platelets and the generation of procoagulant microparticles that may express sustained h

178 dothelial- and leukocyte-derived circulating procoagulant microparticles were isolated and quantified

179 venous thrombosis, and (2) cancer promotes a procoagulant milieu, we hypothesize that Gas6 may be inv

180 The proinflammatory and procoagulant molecule C-reactive protein (CRP), which in

181 issue factor and release proinflammatory and procoagulant molecules such as granular enzymes, cytokin

182 was required for the final release of highly procoagulant MPs from filopodia.

183 mmarize our current knowledge of the role of procoagulant MPs in hemostasis and thrombosis.

184 zed that patients with ALF develop increased procoagulant MPs in proportion to the severity of system

185 Highly procoagulant MPs of specific size ranges are associated

186 ough tissue factor upregulation, shedding of procoagulant MPs, endothelial nitric oxide synthase down

187 ely onto phosphatidylserine-positive, highly procoagulant MPs.

188 c activity in vivo attenuated the release of procoagulant MPs.

189 as associated with a progressive shedding of procoagulant MPs.

190 s patients have higher levels of circulating procoagulant MVs than healthy controls.

191 ovide a biochemical rationale for the strong procoagulant nature of venom prothrombinase.

192 ges affecting platelet numbers and function, procoagulant or anticoagulant factors, fibrinolysis, and

193 This study shows that distinct procoagulant pathways operate in mouse VT, dependent on

194 r and tissue factor pathway inhibitor toward procoagulant phenotype in human coronary artery endothel

195 e fibrin structure and stability reflect the procoagulant phenotype of the endogenous cells, and sugg

196 w that histone-activated platelets possess a procoagulant phenotype that drives plasma thrombin gener

197 perative signature (number, cellular origin, procoagulant phenotype) could predict midterm graft fail

198 he switch of these cells from a resting to a procoagulant phenotype.

199 apoptotic, proinflammatory, proadhesive, and procoagulant phenotype.

200 eceptor (PAR)1 and PAR4 in the generation of procoagulant phenotypes on platelet membranes.

201 activation is associated with the release of procoagulant phosphatidylserine-rich small membrane vesi

202 zymatic generation and active provision of a procoagulant phospholipid surface enriched in 12/15-lipo

203 on of whether purified muscle myosins retain procoagulant phospholipid through purification.

204 o fibrin displayed shape change, exposure of procoagulant phospholipids, and the formation of small c

205 Intravenously administered procoagulant PL caused clotting factor activation and de

206 Thus, procoagulant PL regulate AAA development through complex

207 oducts can help deliver appropriate doses of procoagulant plasma and platelets quicker and more safel

208 Targeting polyphosphate abolishes procoagulant platelet activity in a factor XII-dependent

209 We therefore propose the term procoagulant platelet as the unifying terminology.

210 in alphaIIbbeta3 and the physiologic role of procoagulant platelet formation in the regulation of pla

211 The identity of the procoagulant platelet has been elusive.

212 When platelets are strongly stimulated, a procoagulant platelet subpopulation is formed that is ch

213 stigate the mechanisms responsible for these procoagulant platelet-associated changes in integrin alp

214 Procoagulant, platelet, erythrocyte, and endothelial but

215 Procoagulant, platelet, erythrocyte, and endothelial mic

216 ly and markedly enhances the ability to form procoagulant platelets and increases platelet-dependent

217 major coagulation factors on the surface of procoagulant platelets and suggest its importance in pro

218 e perspectives on the biomarker potential of procoagulant platelets for thrombotic events as well as

219 ceiving aspirin therapy indicates that these procoagulant platelets form despite aspirin therapy, but

220 Procoagulant platelets formed upon strong platelet stimu

221 , and thrombin; (3) significant increases of procoagulant platelets induced by convulxin/thrombin and

222 e we show that alphaIIbbeta3 inactivation in procoagulant platelets relies on a sustained high intrac

223 blood coagulation factors on the surface of procoagulant platelets was investigated using confocal m

224 ion, which is essential for the formation of procoagulant platelets, is impaired in the absence of cy

225 mPTP-dependent alkalinization occurred in procoagulant platelets, suggesting a possible alternativ

226 anism for enhancement of calpain activity in procoagulant platelets.

227 to the switch mechanisms from aggregating to procoagulant platelets.

228 Polyphosphate is an inorganic procoagulant polymer.

229 The greater procoagulant potential is related to more efficient FV r

230 we assessed the influence of histones on the procoagulant potential of human platelets in platelet-ri

231 summary, our results provide evidence of the procoagulant potential of smaller and larger endothelial

232 nal microparticles at the levels that have a procoagulant potential.

233 from apoptotic platelets and correlates with procoagulant potential.

234 and requires activation to fully exhibit the procoagulant potential.

235 ges, tamponades, tourniquets, dressings, and procoagulant powders.

236 and induce an intracellular signaling and a procoagulant/proinflammatory phenotype that leads to thr

237 ociated initiator of coagulation and related procoagulant properties in the blood.

238 nication destroyed complement-activating and procoagulant properties in vitro and rendered the DVs bi

239 Red blood cells (RBCs) demonstrate procoagulant properties in vitro, and elevated hematocri

240 Procoagulant properties were evaluated by fluorescence f

241 eleased vesicles displays the most prominent procoagulant properties.

242 ted with factor FX (FX)-S195A, but not other procoagulant protease zymogens, also results in initiati

243 Thrombin, a procoagulant protease, cleaves and activates protease-ac

244 The procoagulant protein tissue factor (F3) is a powerful gr

245 asma and that this induces expression of the procoagulant protein tissue factor (TF) in monocytes.

246 articularly phosphatidylserine (PS), and the procoagulant protein tissue factor (TF), which is the ma

247 leukocytes induces expression of the potent procoagulant protein tissue factor that triggers thrombo

248 nd reducing the pathologic expression of the procoagulant protein tissue factor.

249 s encoding proinflammatory cytokines and the procoagulant protein, tissue factor.

250 enetic loci associated with plasma levels of procoagulant proteins and risk of thrombotic disease.

251 pathways by which platelets and circulating procoagulant proteins synergistically orchestrate VTE re

252 ing that Orai1 is crucial for the platelets' procoagulant response rather than for other Ca(2+)-depen

253 inical factors that trigger or intensify the procoagulant response to sepsis is warranted.

254 straints intended to restrict an unregulated procoagulant response.

255 e increased inflammatory, prothrombotic, and procoagulant responses following severe acute respirator

256 ctivation by bacterial omptins to potentiate procoagulant responses to bacterial infection.

257 isplay sustained inflammatory, vascular, and procoagulant responses.

258 the thrombin/thrombomodulin complex, plays a procoagulant role during fibrin clot formation.

259 A subpopulation of platelets fulfills a procoagulant role in hemostasis and thrombosis by enabli

260 Our results demonstrate an unexpected procoagulant role of the protein C pathway that may have

261 Several hemostatic factors showed a procoagulant shift with decreasing kidney function in co

262 nd reduced platelet activation/expression of procoagulant signaling.

263 equences located near HC796-835 as potential procoagulant sites.

264 Ballooning and procoagulant spreading of platelets are driven by fluid

265 , Cl(-), or water entry impaired ballooning, procoagulant spreading, and microparticle generation, an

266 ontact surfaces, by a process that we termed procoagulant spreading.

267 ction with AT, and thereby contribute to the procoagulant state associated with P falciparum infectio

268 Septic shock is a highly inflammatory and procoagulant state associated with significant mortality

269 t is recognized that leukocytes may induce a procoagulant state at sites of inflammation, the critica

270 microvasculature assumes an inflammatory and procoagulant state in a variety of different diseases, i

271 protein C system promotes a proinflammatory, procoagulant state in brain microvessels.

272 Although TF has been clearly linked to a procoagulant state in obesity, emerging genetic and phar

273 Asthma is associated with a procoagulant state in the bronchoalveolar space, further

274 r a regulatory protein deficiency, sets up a procoagulant state in these diseases as well as in the a

275 ositive patients (p=0.04), suggesting a more procoagulant state in this early symptomatic subgroup.

276 We analyzed the native procoagulant state of LT recipients, identified through

277 sms by which hypercholesterolemia produces a procoagulant state remain undefined.

278 modulates the dysregulated proinflammatory, procoagulant state that leads to lung injury.

279 d to microangiopathic hemolytic anemia and a procoagulant state with or without damage to the kidneys

280 y response syndrome (SIRS) associated with a procoagulant state.

281 esis by damaging endothelium and promoting a procoagulant state.

282 ciparum infection is often associated with a procoagulant state.

283 irrhosis, the hemostasis is shifted toward a procoagulant state.

284 Overall, these alterations result in a procoagulant state.

285 charide infusion attenuates proinflammatory, procoagulant states that induce lung vascular injury in

286 y a role for TFPI in dampening intravascular procoagulant stimuli that lead to thrombin generation, e

287 coupled to provide a sustained, disseminated procoagulant stimulus for use as a biologic toxin.

288 thromboelastometry EVs exerted a significant procoagulant stimulus, which could be partly reversed by

289 amatically reduced catalytic efficiency with procoagulant substrates while largely preserving thrombo

290 These platelets form a procoagulant surface, supporting fibrin formation, and r

291 region, contribute to provision of myosin's procoagulant surface.

292 SC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigge

293 eregulation of vascular effectors, including procoagulant tissue factor (TF), this study explores whe

294 Given that thrombin induces procoagulant tissue factor (TF), we examined how TF acti

295 iven thrombosis in fetal loss, expression of procoagulant tissue factor was significantly increased i

296 to increased C3 deposition, C5a release, and procoagulant tissue-factor expression.

297 oduce an array of toxic compounds, including procoagulants to defend themselves and incapacitate prey

298 lected pathogens appear to benefit from host procoagulants to drive bacterial virulence.

299 tor Xa might prove useful as new therapeutic procoagulants to treat deficiencies upstream of the comm

300 od vessel injury by the acute release of the procoagulant von Willebrand factor, which is stored in u